Research LettersPrope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients
References (5)
- et al.
Induction of Immunological tolerance by porcine liver allografts
Nature
(1969) - et al.
The essential roles of parenchymal tissues and passenger leukocytes in the tolerance induced by liver grafting in rats
Nat Med
(1995)
There are more references available in the full text version of this article.
Cited by (403)
Alemtuzumab in renal transplantation. Reviews of literature and usage in the United Kingdom
2022, Transplantation ReviewsCitation Excerpt :Roy Calne and colleagues carried out the first non-randomised trial of Campath 1H in kidney transplant recipients in 1997 in 13 kidney transplant recipients. The study results demonstrated both a good safety profile and good graft survival [22]. In 2001 the FDA and the European Medicines Agency approved the use of alemtuzumab to treat B-cell chronic lymphocytic leukaemia, and in 2013/2014, it received approval to be used in the treatment of multiple sclerosis [33].
Solid Organ Transplantation: Rejection, Immunosuppression, and Tolerance
2022, Clinical Immunology: Principles and Practice, Sixth EditionImmunosuppression in Liver Transplantation
2022, Comprehensive PharmacologyPerioperative Management of Renal Failure and Renal Transplant
2021, Perioperative Medicine: Managing for Outcome, Second EditionTransplant research in nonhuman primates to evaluate clinically relevant immune strategies in organ transplantation
2019, Transplantation ReviewsConcepts and Challenges in Organ Transplantation
2019, Clinical Immunology: Principles and Practice
Copyright © 1998 Elsevier Ltd. All rights reserved.